EC Number | Application | Comment | Organism |
---|---|---|---|
3.4.21.20 | medicine | cathepsin G is a potentially novel therapeutic target in the treatment of breast cancer bone metastasis | Mus musculus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.21.20 | Na-tosyl-Phe-chloromethylketone | effectively inhibited the action of cathepsin G against the substrate at a concentration of 1 mmol/l | Mus musculus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.21.20 | additional information | Mus musculus | enzyme enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-KB ligand. It is significantly up-regulated at the tumor-bone interface and is capable of generating sRANKL, which potentially enhances osteoclast activation and osteolysis | ? | - |
? | |
3.4.21.20 | additional information | Mus musculus BALB/c | enzyme enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-KB ligand. It is significantly up-regulated at the tumor-bone interface and is capable of generating sRANKL, which potentially enhances osteoclast activation and osteolysis | ? | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.21.20 | Mus musculus | - |
Balb/c mice | - |
3.4.21.20 | Mus musculus BALB/c | - |
Balb/c mice | - |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.21.20 | 4T1 cell | murine breast adenocarcinoma cell line | Mus musculus | - |
3.4.21.20 | Cl-66 cell | murine breast adenocarcinoma cell line | Mus musculus | - |
3.4.21.20 | Cl-66M2 cell | murine breast adenocarcinoma cell line | Mus musculus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.21.20 | additional information | enzyme enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-KB ligand. It is significantly up-regulated at the tumor-bone interface and is capable of generating sRANKL, which potentially enhances osteoclast activation and osteolysis | Mus musculus | ? | - |
? | |
3.4.21.20 | additional information | enzyme enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-KB ligand. It is significantly up-regulated at the tumor-bone interface and is capable of generating sRANKL, which potentially enhances osteoclast activation and osteolysis | Mus musculus BALB/c | ? | - |
? | |
3.4.21.20 | N-succinyl-Ala-Ala-Pro-Phe-4-nitroanilide + H2O | - |
Mus musculus | N-succinyl-Ala-Ala-Pro-Phe + 4-nitroaniline | - |
? | |
3.4.21.20 | N-succinyl-Ala-Ala-Pro-Phe-4-nitroanilide + H2O | - |
Mus musculus BALB/c | N-succinyl-Ala-Ala-Pro-Phe + 4-nitroaniline | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.21.20 | cathepsin G | - |
Mus musculus |